

FORM PTO-1390
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

701039-048929

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/070647

INTERNATIONAL APPLICATION NO.
PCT/US00/24839

INTERNATIONAL FILING DATE
11 September 2000

PRIORITY DATE CLAIMED
10 September 1999

TITLE OF INVENTION
METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

APPLICANT(S) FOR DO/EO/US BERNFIELD, M. and PARK, Pyong Woo

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

20. ☐ Other items or information:

PCT/IB/301 with Annex (2 pp.); PCT/IB/304 (1 pg.); PCT/ISA/220 with Notes (4 pp.); PCT/ISA/210 with Annex (3 pp.); PCT/IB/308 (1 pg.); PCT/IB/332 (1 pg.); PCT/IPEA/416 (1 pg.); Form PCT/IPEA/409 (4 pp.); Express Mail Certificate - Label No. EL565098413US (1 pg.); and Return Receipt Postcard.

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 10/070647 INTERNATIONAL APPLICATION NO. PCT/US00/24839				ATTORNEY'S DOCKET NUMBER 701039-048929					
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">\$</td> <td style="width: 50%; border: none; text-align: right;">710.00</td> </tr> </table>		\$	710.00		
\$	710.00								
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">\$</td> <td style="width: 50%; border: none; text-align: right;">130.00</td> </tr> </table>		\$	130.00		
\$	130.00								
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE						
Total claims	12 - 20 =	0	x \$18.00						
Independent claims	3 - 3 =	0	x \$84.00						
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00						
TOTAL OF ABOVE CALCULATIONS =				\$ 840.00					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">\$</td> <td style="width: 50%; border: none; text-align: right;">420.00</td> </tr> </table>		\$	420.00		
\$	420.00								
SUBTOTAL =				\$ 420.00					
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">\$</td> <td style="width: 50%; border: none;"></td> </tr> </table>		\$			
\$									
TOTAL NATIONAL FEE =				\$ 420.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">\$</td> <td style="width: 50%; border: none;"></td> </tr> </table>		\$			
\$									
TOTAL FEES ENCLOSED =				\$ 420.00					
				<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Amount to be refunded:</td> <td style="width: 50%; border: none;">\$</td> </tr> <tr> <td style="width: 50%; border: none;">charged:</td> <td style="width: 50%; border: none;">\$</td> </tr> </table>		Amount to be refunded:	\$	charged:	\$
Amount to be refunded:	\$								
charged:	\$								
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>420.00</u> to cover the above fees is enclosed.									
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-0850</u> . A duplicate copy of this sheet is enclosed.									
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO David S. Resnick NIXON PEABODY LLP 101 Federal Street Boston, MA 02110			<div style="text-align: center;"> SIGNATURE </div> <div style="text-align: center;"> David S. Resnick / Lana A. Shvartsman NAME </div> <div style="text-align: center;"> <u>34,235 / 48,502</u> REGISTRATION NUMBER </div>						

Practitioner's Docket No. 701039-048929-PCT

CHAPTER II

**TO THE UNITED STATES ELECTED OFFICE (EO/US)
(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)**

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US00/24839	11 September 2000 (11.09.01)	10 September 1999 (11.09.99)

TITLE OF INVENTION


METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

APPLICANTS

BERNFIELD, M. and PARK, Pyong Woo

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231

ATTENTION: EO/US

CERTIFICATE OF MAILING	
I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. <u>EL565098413US</u> in an envelope addressed to Box PCT, Assistant Commissioner of Patents, Washington, D.C. 20231, Attention: EO/US.	
Date: <u>3/8/02</u>	 Nicole M. Gignac

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231

Attention: EO/US

PRELIMINARY AMENDMENT

This Preliminary Amendment is being filed in the U.S. Patent and Trademark Office concurrently with the U.S. National Phase Entry of the above-identified application.

Preliminary to calculation of the filing fee and examination on the merits, please amend the application identified in caption as follows:

Applicant: Children's Medical Center Corporation
Inventors: BERNFIELD, M. and PARK, P.
U.S. Serial No.: To be assigned (PCT/US00/24839) Group Art Unit: To be assigned
Filed: Herewith (11 September 2000) Examiner: To be assigned
For: METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

IN THE SPECIFICATION:

Please insert the following heading and paragraph as the first paragraph on the first page in the application:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Phase Entry Application of co-pending International Application PCT/US00/24839 filed on 11 September 2000 which designated the U.S and which claims the benefit of U.S. Provisional Application 60/153,310 filed 10 September 1999.

Applicant: Children's Medical Center Corporation
 Inventors: BERNFIELD, M. and PARK, P.
 U.S. Serial No.: To be assigned (PCT/US00/24839) Group Art Unit: To be assigned
 Filed: Herewith (11 September 2000) Examiner: To be assigned
 For: METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

REMARKS

By the present Preliminary Amendment, Applicant has added the heading and cross-reference information suggested by the U.S. Patent and Trademark Office at the appropriate places in the specification.


In the event that there are any questions relating to this Amendment or to the application in general, it is kindly requested that the Examiner contact the undersigned attorney concerning the same to expedite prosecution of this application.

Entry of the foregoing and prompt and favorable consideration of the subject application on the merits are respectfully requested.

Date: 3/8/02

Customer No.: 26770

Respectfully submitted,



 David S. Resnick (Reg. No. 34,235)
 Lana A. Shvartsman (Reg. No. 48,502)
 NIXON PEABODY LLP
 101 Federal Street
 Boston, MA 02110
 Tel. (617) 345-6057
 Fax (617) 345-1300

Applicant: Children's Medical Center Corporation
Inventors: BERNFIELD, M. and PARK, P.
U.S. Serial No.: To be assigned (PCT/US00/24839) Group Art Unit: To be assigned
Filed: Herewith (11 September 2000) Examiner: To be assigned
For: METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

**VERSION WITH MARKINGS TO SHOW CHANGES MADE TO THE
SPECIFICATION**

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Phase Entry Application of co-pending International
Application PCT/US00/24839 filed on 11 September 2000 which designated the U.S and which
claims the benefit of U.S. Provisional Application 60/153,310 filed 10 September 1999.

METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

BACKGROUND OF THE INVENTION

This invention was made with government support under Grant No. R01 CA28735-15 by the National Institute of Health. The government has certain rights in the invention.

1. Field of the Invention

5 The present invention relates to methods and compositions for treating bacterial infections, especially infections by opportunistic pathogens.

2. Background

10 Microbial pathogenicity has been defined as the structural and biochemical mechanism whereby microorganisms cause disease. The first stage of microbial infection is the establishment of the pathogen at the portal of entry. Pathogens usually colonize host tissues that are in contact with the external environment. for example the urogenital tract, the digestive tract, the respiratory tract and the conjunctiva. Organisms that infect these regions have usually developed tissue adherence
15 mechanisms and some ability to overcome or withstand host defense mechanisms usually resulting in colonization, multiplication, invasion or persistence of a pathogen on or within a host. Therefore, pathogenicity in bacteria may be associated with unique structural components of the cells, for example: capsules, fimbriae, lipopolysaccharide (LPS) or other cell wall components; or, mechanisms such as active
20 secretion of substances that either damage host tissues or protect the bacteria against host defenses. In most cases, a break in the host's first line defenses for example trauma, surgery, serious burns or indwelling devices can give rise to opportunistic infections. Examples of such pathogens are *Staphylococcus aureus*, hereafter referred to as *S. aureus*, and *Pseudomonas aeruginosa*, hereafter referred to as *P. aeruginosa*.

25 Human staphylococcal infections are frequent, but usually remain localized at the portal of entry by the normal host defenses. The portal may be a hair follicle, but

usually it is a break in the skin, which may be a minute needle stick or a surgical wound. Foreign bodies, including sutures, are readily colonized by staphylococci, which makes infection difficult to control (70). Another portal of entry is the respiratory tract. Staphylococcal pneumonia is a frequent complication of influenza (71). Serious consequences of staphylococcal infections occur when the bacteria invade the blood stream. A resulting septicemia may be rapidly fatal; a bacteremia may result in seeding other internal abscesses, other skin lesions, or infections of the lung, kidney, heart skeletal muscles or meninges. Staphylococcal disease has been a perennial problem in the hospital environment since the beginning of the antibiotic era. During the 1950's and early 1960's, staphylococcal infection was synonymous with nosocomial infection. Gram-negative bacilli for example, *Escherichia coli* and *P. aeruginosa* have replaced the staphylococci as the most frequent causes of nosocomial infections, although the staphylococci have remained a problem (70, 71).

P. aeruginosa is a major causative agent of gram-negative bacterial lung infections among compromised patients. Immunocompromised patients, such as neutropenic cancer and bone transplantation patients, are particularly susceptible to opportunistic infections (72). In this group of patients, *P. aeruginosa* is responsible for pneumonia and septicemia with attributable deaths reaching 30% (73, 74). *P. aeruginosa* is also one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, with directly attributable death rates reaching 38% (75, 96). In nosocomial infections, *P. aeruginosa* is responsible for 16% of nosocomial pneumonia cases (70), 12% of hospital-acquired urinary tract infections (76), 8% of surgical wound infections (77), and 10% of bloodstream infections (9). In the expanding HIV-infected population, *P. aeruginosa* bacteremia is associated with 50% of deaths (79). In addition, *P. aeruginosa* corneal infection is one of the leading causes of contact lens-related infection/loss of vision. *P. aeruginosa* also has a major impact on the rates of illness and death of patients with cystic fibrosis (80). Recent studies have also shown that *P. aeruginosa* associated pneumonia may play a role in many other lung manifestations, such as emphysema and chronic obstructive pulmonary disease. Despite the clinical data demonstrating the significance of *P. aeruginosa* in a range of infections, particularly lung infections, its pathogenic mechanism is not understood. The capacity of *P. aeruginosa* to

produce such diverse, often overwhelming infections is due to an arsenal of virulence factors.

Many extracellular virulence factors secreted by *P. aeruginosa* have been shown to be controlled by a complex regulatory circuit involving cell-to-cell signaling systems that allow the bacteria to produce these factors in a coordinated, cell-density-dependent manner (72). With respect to cystic fibrosis, hereafter referred to as C.F., the mechanisms contributing to pathogenesis are still largely unknown. In patients with C.F. the major clinical manifestations occur in the gastrointestinal tract and in the airways and lungs (81). The gastrointestinal tract symptoms of C.F. have been adequately managed in the last 30 to 40 years, but the major clinical problem facing these patients is the progressive loss of pulmonary function, usually due to chronic bacterial infections by mucoid *P. aeruginosa* - some strains of *P. aeruginosa* produce large amounts of extracellular polysaccharide and are referred to as mucoid strains (81). Once established as an infection in the lungs of C.F. individuals, *P. aeruginosa* can persist for decades. Although C.F. patients have intact immune systems they do not mount an effective response against *P. aeruginosa*. Ordinarily, opsonic antibodies are a crucial component of immunity to *P. aeruginosa*, but during such chronic infections, *P. aeruginosa* produces MEP/alginate - a factor central to microbial persistence - as it is responsible for eliciting antibodies that fail to mediate phagocytosis of *P. aeruginosa*. Moreover, the eradication of colonization with *P. aeruginosa* is almost impossible in C.F. patients because of the emergence of multidrug-resistant strains and the protective effects of alginate (81).

The increasing emergence of bacterial strains resistant to antibacterial drugs has been driven mainly by overuse of antibacterial agents, thereby selecting for bacteria resistant to these agents (82). Beginning with the use of penicillin in the 1940's, drug resistance developed in staphylococci within a very short time after introduction of an antibiotic into clinical use. *S. aureus* responded to the introduction of antibiotics by the usual bacterial means to develop resistance, for example by mutation in chromosomal genes followed by selection of resistant strains, and by acquisition of resistance genes as extra chromosomal plasmids, transducing particles, transposons, or other types of DNA inserts. *S. aureus* expresses its resistance to drugs and antibiotics by a variety of mechanisms (83, 84, 85, 86). Hospital strains of *S.*

aureus are commonly resistant to a variety of different antibiotics. Methicillin resistance has been widespread since the late 1960s, and some *S. aureus* strains are now resistant to all clinically useful antibiotics except the glycopeptides vancomycin and teicoplanin (87). In the last several years, vancomycin-resistant *S. aureus* strains have emerged, sparking fears of an untreatable strain of this important nosocomial pathogen (88,89,90,91). In addition, *S. aureus* expresses resistance to antiseptics and disinfectants, such as quaternary ammonium compounds, which may aid in its survival in the hospital environment (92). Another example is *P. aeruginosa* which has become one of the most problematic human pathogens, as it shows intrinsic resistance to many structurally unrelated antibiotics. Resistance mechanisms include low outer membrane permeability or multidrug efflux pumps (tetracycline, imipenem, fluoroquinolones, aminoglycosides) or production of antibiotic modifying enzymes (aminoglycosides, β -lactams) (94). Furthermore, previous exposure to antibiotics often leads to multidrug-resistant *P. aeruginosa* strains (95). The pathogenesis of *P. aeruginosa* and *S. aureus* is clearly multifactorial as underlined by the large number of virulence factors and the broad spectrum of diseases these bacteria cause. It is, therefore, imperative to elucidate the mechanisms of bacterial pathogenesis, for example *S. aureus* and *P. aeruginosa*, and to develop alternative prophylactic and therapeutic agents that target specific host-pathogen interactions involved in bacterial pathogenesis.

Shedding is a process in which cell surface proteins are cleaved by proteinases known collectively as sheddases or secretases, and released from the surface as soluble effectors (1-3). It is an important biological mechanism of protein secretion and activation for the approximately 1% of total cell surface proteins that can also function as soluble ectodomains. Numerous types of surface molecules are shed as soluble ectodomains and the list includes cytokines, growth factors and their receptors, enzymes and cell adhesion molecules such as selectins (4), CD14 (5), EGF (6), TNF- α (7,8) and their receptors (9,10), IL-6 receptor (11), Fas ligand (12) and TGF- α (13), to name a few. It is well established that these shed ectodomains play pivotal roles in diverse pathophysiological events including septic shock, host defense and wound healing. Furthermore, shedding provides an additional level of regulating the activity of affected effectors since shedding itself has been found to be regulated

by various extracellular ligands (14-16) and intracellular signaling pathways (3,13,16,17).

Pathogenic microorganisms, constantly evolving in the hostile host environment, have learned to frequently take advantage of existing host systems for their pathogenesis. For example, a diverse group of pathogens including *Yersinia* spp. (20), *Bordetella pertussis* (21,22) and adenovirus (23) express RGD-containing cell surface ligands and use these “molecular mimics” to interact with host integrin receptors for their colonization (24). Bacteria also contain molecules in their pathogenic arsenal that can derange host homeostasis to their benefit. Several bacteria secrete toxins that can modify the host cell cytoskeleton (25) and secrete enzymes that can degrade extracellular matrix (ECM) components, immunoglobulins and complement, either directly (26,27) or indirectly by activating the host’s matrix metalloproteinases (28). Furthermore, LPS from Gram negative bacteria, the causative agent of endotoxic shock, affects expression of many host defense effectors such as TNF- α and IL-1, -6, -8 and -10 (29).

Recent studies indicate that bacterial pathogens may also utilize the host’s shedding mechanism to the benefit of their pathogenesis. For instance, the pore-forming toxins, streptolysin O and *E. coli* hemolysin, have been found to trigger shedding of LPS (CD14) and IL-6 receptors (30). Culture supernatants from *P. aeruginosa*, *S. aureus*, *Serratia marcescens* and *Listeria monocytogenes* can also augment shedding of the IL-6 receptor (31), and culture supernatants from *Staphylococcus epidermidis* can activate shedding of TNF- α (32), although the responsible shedding enhancers have not been defined in these studies. Furthermore, increased serum levels of soluble ectodomains of several surface effectors, such as CD14, TNF- α and IL-4 receptors, have been documented during infection (33-35). These findings suggest that bacteria-enhanced shedding can modulate the activation and function of host effectors, and play a role in bacterial pathogenesis.

Syndecans are a family of cell surface heparan sulfate proteoglycans (HSPGs) which, along with the glypicans, are the major source of cell surface heparan sulfate (HS) (36). There are currently four mammalian syndecans, syndecan-1 through -4, each encoded by distinct genes. Functionally, syndecans can bind and modulate the activity of a diverse group of soluble and insoluble ligands, such as ECM

components, growth factors, chemokines, cytokines and proteases, through the action of their HS chains. Syndecans have also been proposed to act as adhesion and internalization receptors for pathogenic microorganisms (37,38). The extracellular domains of syndecans can be shed as soluble, intact HSPGs which, because they bind
5 the same ligands as their precursor proteoglycans on the cell surface, can serve as soluble effectors. For example, shed syndecan-1 ectodomains have been found to regulate the proliferative response of cells to FGF-2 (39) and potentiate the activity of neutrophil enzymes, such as elastase and cathepsin G (40), by binding to the enzymes and protecting them from inhibition by their physiological inhibitors. All syndecans
10 are shed constitutively in culture, but available evidence also indicates that syndecan shedding is highly regulated and is a host response to tissue injury (16). There has been no reported association between syndecan-1 shedding and bacterial pathogenesis.

There continues to exist a need in the art for new antimicrobial methods and
15 materials, especially against opportunistic pathogens.

SUMMARY OF THE INVENTION

The present invention provides methods and compositions for treating bacterial infections, especially infections by opportunistic pathogens in a subject by
20 administering a compound that inhibits syndecan-1 shedding. The invention is based on the discovery that two diverse opportunistic pathogens, *S. aureus* and *P. aeruginosa*, enhance syndecan-1 shedding and that this shedding is critical for *Pseudomonas* and staphylococcal pathogenesis via the respiratory tract. The discovery is also based on the surprising finding that inhibition of syndecan-1
25 shedding prevents *Pseudomonas* pneumonia in a mammalian model. The *P. aeruginosa* shedding enhancer has been purified and identified as the mature 20 kDa LasA protein, a known virulence factor of *P. aeruginosa*.

According to one aspect of the invention a method is provided for treating a bacterial infection comprising:

30 a) determining whether the bacterium causing the infection is capable of enhancing host cell syndecan-1 shedding; and

b) administering an effective amount of a compound that inhibits syndecan-1 shedding to a subject suffering from said infection, wherein the compound is selected from (a) inhibitors of a bacterial factor responsible for syndecan-1 cleavage, e.g., LasA in the case of *P. aeruginosa*, (b) compounds that bind the syndecan and disrupt cleavage, (c) syndecan-1 decoys, and (d) inhibitors of the host cell shedding mechanism, except when the bacterium is *Pseudomonas aeruginosa*, the compound is not genistein or tyrphostin A47. More preferably, when the bacterium is *Pseudomonas aeruginosa*, the compound is not a general protein tyrosine kinase inhibitor.

10 Inhibitors of the host cell shedding mechanism include hydroxamate derivatives and protein tyrosine kinase inhibitors. BB1101 is a preferred hydroxamate derivative. Genistein, herbinylen and tyrphostins, such as A25, are preferred protein tyrosine kinase inhibitors.

15 Compounds that bind the syndecan and disrupt cleavage include polyclonal and monoclonal antibodies and peptides.

The method of the present invention is useful in treating infections of the respiratory system, the urinary tract, the skin, and blood stream. The method is particularly useful in treating *Pseudomonas* or *Staphylococcus* lung infections.

20 In other embodiments the invention provides methods for screening compounds that inhibit the syndecan-1 shedding. The methods comprise contacting cells which express syndecan-1, such as NMuMG cells, with the compound being screened and measuring syndecan-1 cleavage.

25 The invention also provides a method for diagnosing an infection by a bacterial organism that is capable of being treated by the methods of the present invention. The method comprises testing a bacterial sample for the ability to induce syndecan-1 cleavage.

Other aspects of the invention are disclosed *infra*.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figure 1. Culture supernatants of *P. aeruginosa* and *S. aureus* enhance shedding of syndecan-1 by NMuMG cells. Bacteria were grown overnight in TSB at 37°C to stationary growth phase and culture supernatants were collected. Fresh

NMuMG culture media (media control) or filter-sterilized bacterial supernatants diluted to 20% (v/v) with NMuMG media were incubated with confluent NMuMG cells in 96 well plates for 14 h at 37°C. At the end of incubation, conditioned media were collected, centrifuged to remove cells, acidified and dot blotted onto cationic
5 Immobilon N PVDF membranes. Extent of syndecan-1 shedding enhancement was determined by the dot immunoblotting method as described in "Experimental Procedures". Each data point represents mean of duplicate or triplicate measurements, and results are presented as fold over media control. The number and horizontal bar in *P. aeruginosa* and *S. aureus* samples indicate mean values for these
10 bacteria.

Figure 2. Concentration- and time-dependent enhancement of syndecan-1 shedding by *P. aeruginosa* supernatant. Confluent NMuMG cells in 96 well plates were incubated with A) varying concentrations (0.1-20%, v/v) of filter-sterilized *P. aeruginosa*, strain BL2, supernatant for 20 h at 37°C or B) 20 % (v/v) BL2
15 supernatant for 2, 8, or 20 h at 37°C. Cell surface and shed syndecan-1 levels were quantified by the dot immunoblotting method as described previously. Measurements obtained with fresh NMuMG media served as control values. Error bars represent SD determined from triplicate measurements.

Figure 3. *P. aeruginosa* supernatant enhances shedding of syndecan-1 by
20 various host cells. Filter sterilized supernatant (20%, v/v) of the clinical *P. aeruginosa* isolate, BL2, was incubated with 1 day post-confluent NMuMG (96 well), C127 (96 well) and LA-4 (24 well) epithelia, and NIH3T3 fibroblasts (24 well) for 20 h at 37°C. Syndecan-1 shed under these conditions was quantified as described previously. Results are presented as mean fold increase over media control \pm SD.

25 Figure 4. The syndecan-1 shedding enhancer of *P. aeruginosa* is a 10-30 kDa protein. Overnight culture supernatants of strain BL2 were treated with 10 μ g/ml proteinase K for 30 min at 37°C, inactivated with 20 mM PMSF, spun down to remove precipitates and filter sterilized. Alternatively, culture supernatants were centrifuged in MWCO spin microfuge tubes at 10,000g for 40 min and flow through
30 fractions were collected. The retentate materials were collected by resuspending the semi-dried material above the MWCO membrane with fresh TSB. These samples, along with untreated BL2 supernatant, were filter sterilized, diluted to 20% (v/v) with

NMuMG media and incubated with confluent cultures of NMuMG cells in 96 well plates for 14 h at 37°C. Shed syndecan-1 levels were quantified by the dot immunoblotting method as described previously. Error bars represent SD determined from triplicate measurements.

5 Figure 5. Partial purification of *P. aeruginosa* supernatant by ammonium sulfate precipitation and gel chromatography identifies a single 20 kDa protein as a candidate syndecan-1 shedding enhancer. An overnight culture supernatant of strain BL2 was precipitated by 80% ammonium sulfate and fractionated by Bio-Gel P-30 gel chromatography at a flow rate of 4.5 ml/h. The collected fractions were speed-vac
10 dried, resuspended in NMuMG culture media, filter sterilized and assayed for syndecan-1 shedding activity. Shed syndecan-1 levels were quantified by the dot immunoblotting method as described previously. Each data point in the activity chromatogram represents mean values from duplicate determinations. The active fractions (12 & 13) and inactive fractions in the vicinity (10, 11, 13, 14 & 15) were
15 subjected to 12% reducing SDS-PAGE and visualized by Coomassie Brilliant Blue R-250 staining (insert).

 Figure 6. Immunoaffinity chromatography with anti-LasA IgGs demonstrates that the *P. aeruginosa* shedding enhancer is LasA. The partially purified material obtained from ammonium sulfate precipitation and gel chromatography of *P.*
20 *aeruginosa* supernatant was fractionated by mouse polyclonal anti-LasA IgG affinity chromatography. The flow through (FT), wash (WSH) and eluate (EL) fractions were collected, and along with the starting material (fractions 12&13), tested for their ability to enhance shedding of syndecan-1 by NMuMG cells as previously described. Results of the activity assay are presented as mean fold increase over media
25 control±SD. Results from analysis of the fractions by 12% SDS-PAGE and Coomassie staining are shown in the insert.

 Figure 7. Purified LasA enhances shedding of syndecan-1 by various host cells in a concentration-dependent manner. Varying concentrations of LasA (0.5, 5, 10 µg/ml), purified by consecutive steps of ammonium sulfate precipitation, gel
30 chromatography and immunoaffinity chromatography, were incubated with confluent cultures of NMuMG (96 well), LA-4 (24 well), or NIH3T3 (24 well) cells for 8 h at

37°C. Extent of syndecan-1 shedding enhancement was determined as previously described. Error bars represent SD determined from triplicate measurements.

Figure 8. Syndecan-1 ectodomains induced to shed by purified LasA and crude *P. aeruginosa* supernatant are intact proteoglycans and the size of their core proteins are identical to that of the constitutively shed ectodomain. Conditioned media from unstimulated NMuMG cells (lanes 1 & 4) and from NMuMG cells stimulated with 5 µg/ml purified LasA (lanes 2 & 5) or 20% (v/v) crude *P. aeruginosa* supernatant (lanes 3 & 6) were incubated with DEAE-Sepharose for 2 h at 4°C, and bound materials were eluted with 2 M NaCl. Approximately 30 ng of the undigested samples were analyzed by 3.5-10% gradient SDS-PAGE and Western immunoblotting using the 281-2 anti-syndecan-1 monoclonal antibody (undigested, lanes 1-3) or digested with 10 mU/ml heparitinase and 20 mU/ml chondroitin sulfate ABC lyase and then analyzed by SDS-PAGE and Western immunoblotting (digested, lanes 4-6). Molecular masses of the immunoreactive proteins were approximated from the migration pattern of pre-stained size standards.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods and compositions to treat and prevent bacterial infections. As one aspect of the present invention, it has now been discovered that shedding of syndecan-1 plays a role in infection by opportunistic pathogens such as *P. aeruginosa* and *S. aureus* and that inhibiting syndecan-1 shedding can be used to treat infection by such opportunistic pathogens.

As used herein, the terms "treatment" or "treating" include: (1) preventing such disease from occurring in a subject who may be predisposed to these diseases but who has not yet been diagnosed as having them; (2) inhibiting these diseases, i.e., arresting their development; or (3) ameliorating or relieving the symptoms of these diseases, i.e., causing regression of the disease states.

Compounds which can inhibit syndecan shedding are selected from (a) inhibitors of a bacterial shedding enhancer responsible for syndecan-1 cleavage, (b) compounds that bind the syndecan and disrupt cleavage, (c) syndecan-1 decoys, and (d) inhibitors of the host cell shedding mechanism. The compounds preferably inhibit syndecan-1 shedding by at least 50% in the syndecan shedding assay of Subramanian,

et al., *J. Biol. Chem.* 272, 14713-14720 (1997). More preferably the compounds inhibit syndecan-1 shedding by 75%, most preferably 95%. Additional compounds are identified and tested in the screening assays discussed in more detail below.

Determining whether the bacterium causing the infection is capable of enhancing host cell syndecan-1 shedding can be done prior to treatment by using a host cell (e.g., epithelial cells) containing sample bacterium suspected of causing the infection to see if syndecan-1 shedding is occurring. Alternatively, a determination that a particular species of bacteria enhances syndecan-1 shedding can be made at an earlier date and one needs merely determine that the species being treated is one known to enhance such shedding.

The invention provides efficient screening methods to identify pharmacological agents or lead compounds for agents which inhibit syndecan-1 shedding. The methods are amenable to automated, cost-effective high throughput drug screening and have immediate application in a broad range of pharmaceutical drug development programs.

A preferred assay mixture of the invention comprises a cell expressing syndecan-1, for example a normal murine mammary gland (NMuMG) cell. An assay mixture of the invention also comprises a candidate pharmacological agent. Generally a plurality of assay mixtures are run in parallel with different candidate agent concentrations to obtain a differential response to the various concentrations. Typically, one of these assay mixtures serves as a negative control, i.e. at zero concentration or below the limits of assay detection. Candidate agents encompass numerous chemical classes, though typically they are organic compounds and preferably small organic compounds. Small organic compounds suitably may have e.g. a molecular weight of more than about 50 yet less than about 2,500. Candidate agents may comprise functional chemical groups that interact with proteins and/or DNA.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and peptides.

Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.

Additionally, natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means. In addition, known pharmacological agents may be subject to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc.

The resultant mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the syndecan-1 would be cleaved from the cell surface. Incubations may be performed at any temperature which allows syndecan shedding, typically between 25°C and 40°C. Incubation periods are typically between 0.1 and 10 hours, preferably less than 5 hours, more preferably less than 2 hours.

After incubation, the presence or absence of the shed syndecan is detected by any convenient method, including ELISA, radioimmunoassay, or dot immunoblotting of cell-free supernatant.

Particularly useful inhibitors of the host cell syndecan-1 shedding mechanism, and thus effective inhibitors of bacterial infection are hydroxamate derivatives, e.g., BB1101 (British BioTech), and protein tyrosine kinase (PTK) inhibitors, e.g., genistein, herbimycin A and tyrphostin A25.

Preferred protein tyrosine kinase inhibitors are inhibitors of the Src family of protein kinases.

Syndecan-1 decoys can also be used to inhibit syndecan-1 shedding. Syndecan-1 decoys include synthetic peptides (linear or cyclized); recombinant peptides corresponding to the juxtamembrane domain of syndecan-1; shorter peptides corresponding to the cleavage domain of syndecan-1, usually 10-15 amino acids in length; organic compounds, similar in structure to the juxtamembrane region or cleavage site peptide sequence; and anti-idiotypic antibodies directed against the Fab domain of the antibody recognizing the cleavage site sequence.

Antibodies and binding fragments thereof that bind syndecan-1 and prevent cleavage are also useful for inhibition.

The antibodies and binding fragments thereof can be either polyclonal or monoclonal, but preferably are monoclonal. If polyclonal, they can be in the form of antiserum or monospecific antibodies, such as purified antiserum which has been produced by immunizing animals with purified syndecan-1. Preferably, however, the antibodies are monoclonal antibodies so as to minimize the administration of extraneous proteins to an individual. Monoclonal antibodies can be prepared according to well known protocols. See, e.g., Skare et al., *J. Biol. Chem.* 268: 16302-16308 (1993), U.S. Pat. Nos. 4,918,163 and 5,057,598, which are incorporated herein by reference. The antibodies can be whole, Fab's, single chain, single domain heavy chain, etc. Single chain antibodies are preferable. Methods for the production of single chain binding polypeptides are described in detail in, e.g., U.S. Pat. No. 4,946,778, which is incorporated herein by reference.

For administration to humans, e.g., as a component of a composition for *in vivo* treatment, the monoclonal antibodies are preferably substantially human to minimize immunogenicity, and are in substantially pure form. By "substantially human" is meant that the immunoglobulin portion of the composition generally contains at least about 70% human antibody sequence, preferably at least about 80% human, and most preferably at least about 90-95% or more of a human antibody sequence.

For therapeutic applications, the compounds may be suitably administered to a subject such as a mammal, particularly a human, alone or as part of a pharmaceutical composition, comprising the compounds together with one or more acceptable carriers thereof and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical compositions of the invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal), ocular using eye drops, transpulmonary using aerosolubilized or nebulized drug administration. Oral and nasal administration are preferred in the present case. The formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art

of pharmacy. See, for example, *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Philadelphia, PA (17th ed. 1985).

Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier which constitutes one
5 or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers or both, and then if necessary shaping the product.

Compositions of the present invention suitable for oral administration may be
10 presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, or packed in liposomes and as a bolus, etc.

15 A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Molded tablets may be made by molding in a
20 suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets optionally may be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.

Compositions suitable for topical administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and
25 pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.

Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the
30 intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may

be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

5 The compound can be used in a concurrent administration with one or more antibiotics. "Concurrent administration," or co-treatment, as used herein includes administration of the agents, in conjunction or combination, together, or before or after each other. The compound and antibiotics may be administered by different routes. For example, the compound may be administered intravenously while the
10 antibiotics are administered intramuscularly, intravenously, subcutaneously, orally or intraperitoneally. Alternatively, the compound may be administered intraperitoneally while the antibiotics are administered intraperitoneally or intravenously, or the compound may be administered in an aerosolized or nebulized form while the antibiotics are administered, e.g., intravenously. The compound and antibiotics are
15 preferably both administered intravenously. The compound and antibiotics may be given sequentially in the same intravenous line, after an intermediate flush, or may be given in different intravenous lines. The compound and antibiotics may be administered simultaneously or sequentially, as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations at the site of
20 infection.

 Therapeutic effectiveness is based on a successful clinical outcome, and does not require that the antimicrobial agent or agents kill 100% of the organisms involved in the infection. Success depends on achieving a level of antibacterial activity at the site of infection that is sufficient to inhibit the bacteria in a manner that
25 tips the balance in favor of the host. When host defenses are maximally effective, the antibacterial effect required may be minimal. Reducing organism load by even one log (a factor of 10) may permit the host's own defenses to control the infection. In addition, augmenting an early bactericidal/bacteriostatic effect can be more important than long-term bactericidal/bacteriostatic effect. These early events are a significant
30 and critical part of therapeutic success, because they allow time for host defense mechanisms to activate.

It will be appreciated that actual preferred amounts of a given compound used in a given therapy will vary according to the particular compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, the patient's weight, general health, sex, etc., the particular indication
5 being treated, etc. and other such factors that are recognized by those skilled in the art including the attendant physician or veterinarian. Optimal administration rates for a given protocol of administration can be readily determined by those skilled in the art using conventional dosage determination tests.

The present invention is further illustrated by the following Examples. These
10 Examples are provided to aid in the understanding of the invention and are not construed as a limitation thereof.

EXAMPLE 1

Materials

15 Affi-Prep Hz Hydrazide affinity chromatography resins, Bio-Gel P-30 gel chromatography resins, Coomassie Brilliant Blue R-250 and pre-stained SDS-PAGE size standards were purchased from Bio-Rad (Melville, NY). Bisindolylmaleimide I, genistein and Tyrphostin A25 were from Calbiochem (La Jolla, CA). Heparan sulfate lyase (heparitinase) and chondroitin sulfate ABC lyase were obtained from Seikagaku
20 (Ijamsville, MD). Tryptic soy broth (TSB) and tryptic soy agar were purchased from Remel (Lenexa, KS). The cationic PVDF membrane, Immobilon N, was from Millipore (Bedford, MA) and ProBlott PVDF membrane for N-terminal sequencing was from Applied Biosystems (Foster City, CA). Tissue culture media and
25 supplements other than serum were from Mediatech (Herndon, VA), fetal calf and calf serum were from HyClone (Logan, UT) and tissue culture plastics were from Costar (Corning, NY). Enhanced chemiluminescence (ECL) Western blotting detection reagents were from Amersham (Arlington Heights, IL), DEAE Sephacel was from Pharmacia Biotech (Piscataway, NJ) and molecular weight cutoff spin tubes were from Pall Filtron (Northborough, MA). TPCK-treated trypsin, soybean trypsin
30 inhibitor and all other materials were purchased from Sigma (St. Louis, MO).

Cells and immunochemicals

Normal murine mammary gland (NMuMG), mouse lung adenoma (LA-4) and mouse mammary gland (C127) epithelia, and Swiss mouse embryo fibroblasts (NIH3T3) were purchased from the ATCC (Rockville, MD). The cells were cultured
5 as previously described (41) according to the provider's recommendations.

P. aeruginosa laboratory strains 7700 and 10145 were from the ATCC. The clinical *P. aeruginosa* isolates, BL1, BL2, CF1, CF2 and SP1, were from the Division of Infectious Diseases at Washington University School of Medicine (St. Louis, MO), CT4 was kindly provided by Dr. David Roberts at the NCI (Rockville, MD) (42) and
10 PAO1 was maintained in the Pier lab. *S. aureus* laboratory strains 8095, 10832 (Woods), 12598 (Cowan) and 25904 (Newman) were from the ATCC. The clinical blood isolates of *S. aureus*, 070-0875, 093-0861, 108-0009, 111-0449 and 116-0031, were obtained from the Division of Infectious Diseases at Washington University School of Medicine. The *Salmonella enteritidis* clinical isolate was kindly provided
15 by Dr. Robert Thompson of the Department of Vascular Surgery at Washington University School of Medicine. The laboratory strains of *Staphylococcus saprophyticus* (15305), *Staphylococcus xylosus* (29971), *Salmonella enteritidis* (10376), *Salmonella typhimurium* (14028), *Streptococcus pneumoniae* (27336) and *Klebsiella pneumoniae* (27736) were from the ATCC.

20 The rat monoclonal anti-mouse syndecan-1 ectodomain antibody (281-2) was generated in the Bernfield laboratory (43) and is now commercially available from Pharmingen (San Diego, CA). The mouse polyclonal anti-LasA antibody was generated in the Pier laboratory. Horse radish peroxidase-conjugated goat anti-rat secondary antibodies were obtained from either Jackson ImmunoResearch (West
25 Grove, PA) or Cappel (Durham, NC).

Syndecan shedding assays

Quantification of syndecan shedding was performed as previously described (16). Briefly, confluent or 1 day post-confluent cultures of NMuMG and C127 cells
30 in 96 well plates and LA-4 and NIH3T3 cells in 24 well plates were washed once with their respective culture media, and various test samples diluted in culture media were added to the cells. Cells were incubated at 37°C with the samples for the indicated times as described in the figure legends. Cell viability was measured with the

tetrazolium salt (MTT) conversion assay (44). For quantification of shedding, the culture supernatants were collected, spun down to remove cells and the cell-free supernatants were applied to Immobilon N membranes using the dot immunoblotting apparatus. To obtain measurements within the linear range of the dot immunoblotting quantification method, 70 µl out of 100 µl in each 96 well were applied for NMuMG and C127 cells, and 200 µl out of 500 µl in each 24 well were applied for LA-4 and NIH3T3 cells. The samples were acidified by adding NaOAc (pH 4.5), NaCl and Tween-20 to final concentrations of 50 mM, 150 mM and 0.1% (v/v), respectively. By acidifying the samples, mostly highly anionic molecules such as proteoglycans are retained by the cationic PVDF membrane during dot blotting. For quantification of cell surface syndecan-1, following removal of media with or without test samples, cells were washed once with ice-cold TBS (50 mM Tris, pH 7.5, 150 mM NaCl) containing 0.5 mM EDTA and incubated for 15 min at 4°C with ice-cold 10 µg/ml TPCK-treated trypsin in TBS with 0.5 mM EDTA. Trypsin was subsequently inactivated with 100 µg/ml soybean trypsin inhibitor and the reaction mixture was spun down to remove detached cells. For NMuMG cells, 15 µl out of 100 µl trypsinates were blotted onto Immobilon N membranes as described above to obtain measurements in the linear range of the dot immunoblotting method. Development of the blotted membranes were carried out by incubations at 4°C with i) 10% (w/v) non-fat dry milk in TBS for 2 h or longer, ii) 0.2 µg/ml of anti-syndecan-1 antibody (281-2) in BLOTTO (TBS containing 0.5% non-fat dry milk and 0.1% Tween-20) for 14-24 h, iii) BLOTTO for 30 min x 2, iv) 1:8,000 dilution of horse radish peroxidase-conjugated goat anti-rat antibodies in BLOTTO for 14-24 h, v) TBS for 30 min x 2 and vi) the ECL development reagent. The developed blots were scanned and quantified using the public domain NIH Image (V. 1.60) software.

Ammonium sulfate precipitation and Bio-Gel P-30 gel chromatography

Overnight culture supernatant (1 L) of *P. aeruginosa*, strain BL2, was precipitated overnight at 4°C with ammonium sulfate at 80% saturation. The resulting precipitate was pelleted by centrifugation at 15,000 x g for 30 min at 4°C, dissolved in 60 ml de-ionized H₂O, and dialyzed twice against 4 L of de-ionized H₂O.

The dialysate was freeze-dried, resuspended in 30 ml buffer A (50 mM HEPES, pH 7.5, 50 mM NaCl), and 5 ml of this sample was applied to a 1 x 115 cm Bio-Gel P-30 column pre-equilibrated with buffer A. The applied material was fractionated at a flow rate of 4.5 ml/h with buffer A and twenty-four one hour fractions were collected.

5 Aliquots of each fraction were speed-vac dried, resuspended in NMuMG culture media, filter sterilized and tested for their ability to enhance syndecan-1 shedding by NMuMG cells. For gel analysis, fractions were dialyzed against de-ionized water, speed-vac dried, resuspended in SDS-PAGE sample buffer and fractionated by 12% reducing SDS-PAGE.

10

Immunoaffinity chromatography

Carbohydrate moieties within the Fc region of anti-LasA IgGs were oxidized and reacted with hydrazide groups in the Affi-Prep coupling resin to form covalent hydrazone bonds. This coupling method was employed to orient the antigen binding sites outwards from the resin to potentially achieve higher antigen binding capacities. 15 Mouse polyclonal anti-LasA IgGs were purified by protein G affinity chromatography and dialyzed into oxidation buffer (0.1 M NaOAc, pH 5.5, 1 M NaCl). Anti-LasA IgGs (2 mg) in 5 ml of oxidation buffer were oxidized by incubation for 1 h at room temperature in the dark with 500 μ l of 180 mg/ml NaIO₄ in de-ionized H₂O. The 20 oxidized antibody was first dialyzed into H₂O, then into coupling buffer (0.1 M NaOAc, pH 4.5, 1 M NaCl) and incubated overnight with 2 ml of Affi-Prep Hydrazide gel slurry at 4°C. The coupled affinity resin was transferred to a polypropylene column and the active fractions from gel chromatography, resuspended in binding buffer (50 mM HEPES, pH 7.5, 150 mM NaCl), were applied. The 25 samples were re-cycled overnight at a flow rate of 5 ml/h through the affinity resin at 4°C. The flow through fraction was collected and the column was washed with binding buffer. The specifically bound materials were eluted with 0.1 M glycine (pH 2.8), neutralized by 0.1 M HEPES (pH 7.5), dialyzed into autoclaved de-ionized H₂O and concentrated by lyophilization. The concentration of purified LasA was 30 determined by UV spectrophotometry based on the number of tyrosine and tryptophan residues in LasA (1_{A280} =0.41 mg/ml).

Western immunoblotting of partially purified syndecan-1 ectodomains

Conditioned media from unstimulated NMuMG cells (constitutively shed), and from NMuMG cells stimulated with crude *P. aeruginosa* supernatant (20%, v/v) or purified LasA (5 µg/ml) were collected, and NaOAc (pH 4.5) and NaCl were added to final concentrations of 100 and 300 mM, respectively. The acidified conditioned media were incubated with DEAE-Sephacel for 2 h at 4°C. The mixtures were applied to disposable polypropylene columns, washed with 100 mM NaOAc, pH 4.5, 300 mM NaCl buffer and bound materials were eluted with 2M NaCl. The eluates were dialyzed extensively against de-ionized H₂O, concentrated by lyophilization and the amount of partially purified syndecan-1 in the samples was estimated by dot immunoblotting. Approximately 30 ng from each sample was resuspended in digestion buffer (50 mM Tris, pH 7.5, 50 mM NaOAc, 5 mM EDTA, 2 mM PMSF) and digested with 10 mU/ml heparitinase and 20 mU/ml chondroitin sulfate ABC lyase for 3 h at 37°C with fresh enzymes added after 1.5 h. These digested samples and 30 ng of undigested samples were fractionated by SDS-PAGE using 3.5-10% gradient acrylamide gels, electrophoretically transferred to Immobilon N (undigested) or nitrocellulose (digested) membranes, probed with monoclonal rat anti-mouse syndecan-1 antibodies (281-2) and then horse radish peroxidase-conjugated goat anti-rat IgGs, and developed by the ECL detection method as described above.

RESULTS*P. aeruginosa and S. aureus secrete soluble enhancers of syndecan-1 shedding*

To initiate our study examining the interactions between bacterial pathogens and the host's syndecan shedding system, we screened overnight culture supernatants from several Gram negative and positive bacteria for their ability to alter shedding of syndecan-1 by NMuMG cells. NMuMG cells were chosen initially because they express all syndecans, especially syndecan-1 and -4 abundantly (41), the shedding assays are routine in our laboratory with this epithelial cell line and also because the host epithelia is the target cell type of many bacterial pathogens (45,46). Overnight culture supernatants of bacteria were filter sterilized, diluted to 20% (v/v) with NMuMG culture media and incubated with NMuMG cells for 14 h at 37°C. As shown in figure 1, culture supernatants from all tested *P. aeruginosa* (7/7 clinical, 2/2

laboratory) and majority of *S. aureus* (3/5 clinical, 3/4 laboratory) strains enhanced shedding of syndecan-1 by more than 4-fold control levels, whereas strains from several other Gram negative (*Salmonella enteritidis*, *Salmonella typhimurium*, *Klebsiella pneumoniae*) and positive (*Staphylococcus saprophyticus*, *Staphylococcus xylosus*, *Streptococcus pneumoniae*) bacteria did not. Cellular extracts of *P. aeruginosa* and *S. aureus* strains did not affect shedding (data not shown). These results indicate that *P. aeruginosa* and *S. aureus* secrete a soluble enhancer(s) of syndecan-1 shedding, and suggest that this property may be specific for certain bacterial species.

Enhancement of syndecan-1 shedding by P. aeruginosa is rapid and dose-dependent, and various host cells are affected

Because all tested strains of *P. aeruginosa* enhanced syndecan-1 shedding, we focused our subsequent studies on this Gram negative bacteria. The clinical blood isolate, BL2, showed the highest level of enhancement (~14-fold, Fig. 1) and was therefore chosen for further studies. As shown in figure 2, enhancement of epithelial syndecan-1 shedding by BL2 culture supernatant was potent (4-fold increase over control levels with 5% supernatant, Fig. 2A), rapid (6-fold increase by 2 h, Fig. 2B), excessive (11-fold increase by 20 h, Fig. 2B) and dependent on the concentration of BL2 supernatant (Fig. 2A). In contrast to constitutive shedding, which maintains constant levels of cell surface syndecan-1, *P. aeruginosa*-enhanced shedding reduced the amount of surface syndecan-1 (90% reduction at 20% supernatant, Fig. 2A). Under the test conditions, responding NMuMG epithelial cells remained viable.

To examine whether *P. aeruginosa* can affect syndecan-1 shedding by other epithelial cell types and host cells, we tested the effects of BL2 culture supernatant on LA-4 lung and C127 mammary gland epithelia, and NIH3T3 fibroblasts. As shown in figure 3, BL2 culture supernatants augmented syndecan-1 shedding by more than 5-fold for all cell types tested. The extent of shedding enhancement was highest with NMuMG epithelia (~13-fold), followed by C127 epithelia (~10-fold), LA-4 epithelia (~8-fold) and NIH3T3 fibroblasts (~5-fold). These results demonstrate that although the physiological target cell type of *P. aeruginosa*, the epithelia, responds most

extensively to shedding enhancement by *P. aeruginosa* supernatant, other host cells such as fibroblasts can also respond.

Identification of the P. aeruginosa syndecan-1 shedding enhancer as LasA

5 Our experiments testing purified elastase (pseudolysin) and LPS, two major virulence factors of *P. aeruginosa*, failed to demonstrate that these virulence factors are involved in enhancement of syndecan-1 shedding. Thus, to better understand the mechanism behind shedding enhancement by *P. aeruginosa*, we next performed experiments that would provide a general characterization of the *P. aeruginosa*
10 syndecan-1 shedding enhancer. First, we examined whether the activity is susceptible to proteinase K treatment to determine whether the enhancer is a protein. BL2 supernatant was pre-treated with proteinase K and then tested for enhancement of syndecan-1 shedding. As can be seen in figure 4, proteinase K treatment abolished the activity of *P. aeruginosa* supernatant. We next fractionated the crude supernatant
15 with molecular weight cutoff (MWCO) spin tubes to obtain a rough estimate of the enhancer's size. Using 3, 10, 30 and 100 kDa MWCO tubes, we found that the size of the shedding enhancer is larger than 10 kDa but smaller than 30 kDa (Fig. 4, denoted by *). These results suggest that the syndecan-1 shedding enhancer is a 10-30 kDa protein.

20 Based on these properties of the shedding enhancer, proteins in the supernatant were collected by 80% ammonium sulfate precipitation and fractionated by Bio-Gel P-30 (fractionation range=2.5-40 kDa) gel chromatography in an effort to determine the identity of the enhancer. Fractions obtained from gel chromatography were assayed for shedding enhancement and then analyzed by SDS-PAGE. As shown in
25 figure 5, the shedding enhancing activity was isolated in one peak and two fractions, 12 and 13. Analysis of the active and inactive fractions by 12% SDS-PAGE and Coomassie staining revealed the presence of a single, major 20 kDa band in the active, but not in the inactive, fractions (Fig. 5-insert). To determine the identity of the 20 kDa protein, N-terminal sequencing was performed. The first 10 amino acid
30 sequence of the 20 kDa protein matched perfectly with mature LasA protein (Table 1), a known virulence factor of *P. aeruginosa*.

The hypothesis that LasA is the syndecan-1 shedding enhancer of *P. aeruginosa* was tested by fractionating the partially purified active peak obtained from Bio-Gel P-30 gel filtration by immunoaffinity chromatography using mouse polyclonal anti-LasA IgGs covalently coupled to a cross-linked agarose resin. The rationale behind this experiment was that if LasA is indeed the shedding enhancer, then the active component in the partially purified material will be bound to the affinity column, and shedding activity will only be seen with the specifically bound fractions and not with the flow through or wash fractions. As shown in figure 6, the specifically bound eluate (EL), but not the flow through (FT) and wash (WSH) fractions, enhanced syndecan-1 shedding by NMuMG cells. The inactive flow through fraction contained the contaminating smear seen in the active fractions partially purified by gel chromatography, and the eluate fraction contained the highly purified 20 kDa LasA protein (Fig. 6-insert). Furthermore, similar to results obtained with crude *P. aeruginosa* supernatants, purified LasA enhanced syndecan-1 shedding by various host cells (Fig. 7) and did not affect steady-state mRNA levels of syndecan-1 (data not shown). Taken together, these results indicate that LasA is the syndecan-1 shedding enhancer of *P. aeruginosa*, and that LasA can be highly purified by consecutive steps of ammonium sulfate precipitation, Bio-Gel P-30 gel filtration, and anti-LasA IgG immunoaffinity chromatography.

20

LasA enhances syndecan shedding by stimulating the host cell's shedding mechanism

To begin to elucidate the mechanism involved in syndecan-1 shedding enhancement by *P. aeruginosa* LasA, we first examined the macrostructure of shed syndecan-1 ectodomains. Conditioned media from NMuMG cells cultured to confluency (constitutively shed) and from NMuMG cells stimulated with purified LasA or crude *P. aeruginosa* supernatant were subjected to DEAE ion exchange chromatography to obtain partially purified samples of syndecan-1. These undigested samples were directly analyzed by Western immunoblotting (Fig. 8, lanes 1-3) or digested by heparitinase and chondroitin sulfate ABC lyase, and then analyzed by immunoblotting (Fig. 8, lanes 4-6) to determine the size of shed syndecan-1 core proteins. Similar to the constitutively shed syndecan-1 ectodomain (lane 1),

syndecan-1 ectodomains obtained from both purified LasA (lane 2) and crude supernatant (lane 3) conditioned media were intact proteoglycans decorated with glycosaminoglycans as evident from the smear of the immunologically detected syndecan-1 ectodomains. Interestingly, the size of the syndecan-1 core protein
5 stimulated to shed by both purified LasA (lane 5) and crude *P. aeruginosa* supernatant (lane 6) was identical to that of the constitutively shed core protein (lane 4) by SDS-PAGE analysis.

Because the macrostructure of the shed syndecan-1 ectodomain suggested that LasA enhances syndecan-1 shedding by a mechanism similar to that of the host cell's
10 shedding mechanism, effects of a hydroxamate derivative (BB1101), PKC antagonist (bisindolylmaleimide I) and protein tyrosine kinase (PTK) inhibitors (genistein, Tyrphostin A25) were tested. Genistein (47) and Tyrphostin A25 (48) inhibit PTKs by competing for binding with ATP and tyrosine residues to PTKs, respectively. These general PTK inhibitors inhibit syndecan-1 and -4 shedding stimulated by all
15 known agonists such as EGF, thrombin, sphingomyelinase, ceramide and stress conditions (e.g. heat, hyperosmolarity, mechanical shear) whereas the antagonistic effect of the PKC inhibitor, bisindolylmaleimide I, is restricted to syndecan-1 and -4 shedding induced by EGF, thrombin and phorbol esters (16,19). Hydroxamate derivatives inhibit the activity of the putative cleaving enzyme by chelating its active
20 site zinc atom (49). Thus, general PTK inhibitors are inhibitors of regulated syndecan shedding whereas hydroxamate derivatives are inhibitors of both regulated and constitutive shedding. As shown in Table 2, when co-incubated, BB1101 and Tyrphostin A25 inhibited both purified LasA- and *P. aeruginosa* supernatant-enhanced syndecan-1 shedding by more than 70% and 60%, respectively, at the
25 highest concentration tested. Genistein also partially inhibited enhanced shedding (~45%), but bisindolylmaleimide I did not affect syndecan-1 shedding enhanced by LasA and crude *P. aeruginosa* supernatant. However, when the kinase inhibitors and BB1101 were pre-incubated with purified LasA and removed from the samples prior to incubation with NMuMG cells, none of them inhibited enhanced syndecan-1
30 shedding. Taken together, these results indicate that the PTK inhibitors and BB1101 are acting on the host cell, and that LasA is enhancing syndecan-1 shedding via activation of the host cell's shedding mechanism.

DISCUSSION

Enhancement of Host Effector Shedding by Pathogenic Bacteria

The current emergence of antibiotic resistant strains has been driven mainly by
5 overuse of antibacterial agents aimed at inhibiting essential aspects of bacterial
metabolism, such as cell wall and protein synthesis, placing selective pressure on the
bacteria to develop resistance to these agents. Thus, to prevent development of
resistance, it may be ideal to develop prophylactic and therapeutic agents that target
specific host-pathogen interactions involved in bacterial pathogenesis. Enhancement
10 of host effector shedding may be one such target of the pathogenesis cascade. Many
bacterial pathogens as diverse as *P. aeruginosa*, *S. aureus*, *S. epidermidis*, *E. coli*,
Serratia marcescens and *Listeria monocytogenes* have the ability to enhance shedding
of host surface effectors, such as CD14, TNF- α and IL-6 receptor (30-32). These
bacteria are not only distinguished by their cell wall characteristics and sites of
15 colonization, but also by their arsenal of genetically distinct virulence factors. Thus,
the shared ability to enhance shedding of host molecules indicates functional
convergence and suggests that shedding enhancement is a critical aspect of bacterial
pathogenesis. We report here that two major opportunistic bacterial pathogens, *P.*
aeruginosa and *S. aureus*, secrete potent enhancers of syndecan-1 shedding. The
20 ability to augment shedding of syndecan-1 appears to be specific for these bacterial
species since several other Gram negative and positive bacteria failed to do so. The
finding that evolutionarily diverse bacteria, such as *P. aeruginosa* and *S. aureus*, can
enhance syndecan-1 shedding suggests that this activity may be critical for their
pathogenesis at target host sites common to both. In this regard, it is interesting to
25 note that *P. aeruginosa* and *S. aureus* are the dominant pathogens in cystic fibrosis
and burn patients, and that syndecan-1 is the major syndecan of target cell types at
these tissue sites, the lung epithelia and keratinocytes, respectively.

Mechanism of syndecan-1 shedding enhancement by LasA

30 Although we have not yet identified the *S. aureus* shedding enhancer, we have
found that the syndecan-1 shedding enhancer of *P. aeruginosa* is the 20 kDa mature
LasA protein. LasA is secreted as a precursor protein of approximately 40 kDa,

which is then processed to the mature 20 kDa form by unknown mechanisms (50,51). Mature LasA is a zinc metalloendopeptidase with strong staphylolytic and weak elastolytic activities (52,53). The alternative name of LasA, staphylolysin, is derived from its ability to lyse staphylococcal cells. Because of its elastolytic activity, LasA was first thought of as *P. aeruginosa* elastase. It is now known that the role of LasA in elastolysis is to render the insoluble elastin substrate more susceptible to cleavage by the real *P. aeruginosa* elastase and other enzymes with elastolytic activities (50,54).

The capacity of LasA to hydrolyze protein substrates such as elastin, albeit weak, suggests that LasA may enhance syndecan-1 shedding by direct cleavage of the proteoglycan. However, several lines of evidence indicate that this is not the mechanism of syndecan-1 shedding enhanced by LasA. First, the proteolytic specificity of LasA is rather restricted in that potential substrates are those with Gly in the P1 and P2 positions, Gly, Ala or Phe at P1' and apolar residues in the flanking sequences (52). This tight requirement is exemplified by the fact that elastin, with several GGA, GGG and GGF motifs, and *S. aureus*, with the pentaglycine peptide moiety in its cell wall peptidoglycan, are hydrolyzed by LasA, but casein, without these motifs, is not. Syndecan-1 also does not contain these LasA susceptible motifs. Second, our results show that the size of the core protein shed by LasA and endogenous mechanisms of the host cell is identical, and that PTK and hydroxamate inhibitors of LasA-mediated syndecan-1 shedding are inhibiting shedding by acting on the responding host cells and not on LasA. The PTK inhibitors and the hydroxamate derivative, BB1101, can inhibit shedding only when LasA, the reagents and host cells are co-incubated, and not when the inhibitors are pre-incubated with LasA and removed prior to incubation of the pre-treated LasA with host cells. Furthermore, hydroxamate inhibitors are thought to be specific for the HEXXH zinc-binding catalytic domain of metalloendopeptidases, such as the matrix metalloproteinases (49), but the zinc-binding motif of LasA is HXH. Taken together, these findings indicate that LasA enhances shedding of syndecan-1 by activating the host cell's shedding mechanism.

Implications of LasA-enhanced syndecan-1 shedding in P. aeruginosa pathogenesis

Based on the finding that LasA is a virulence factor in animal models of corneal (58) and lung infections (59,60), two tissue sites where syndecan-1 is the predominant syndecan on target epithelia, our working hypothesis for the newly identified function of LasA to enhance shedding of syndecan-1 is that it is a pathogenic activity. There are several ways syndecan-1 shedding may contribute to *P. aeruginosa* pathogenesis. First, host cell invasion by many intracellular pathogens has been found to require signaling by PTKs, ceramide, and more downstream signaling components such as MAP kinases (61-64). These signal transducers are also potent inducers of syndecan shedding (16,19), suggesting that shedding of syndecans from the cell surface accompanies host cell invasion by certain microbial pathogens. Although *P. aeruginosa* is not traditionally thought of as an intracellular pathogen, increasing number of studies have reported that *P. aeruginosa* is internalized by host cells (62,65-68).

Furthermore, *P. aeruginosa* invasion is blocked by PTK inhibitors (62,65), which we have identified as specific inhibitors of LasA-mediated syndecan-1 shedding. Taken together, these correlations suggest that syndecan-1 shedding enhanced by LasA may be an important mediator of *P. aeruginosa* invasion. However, it is important to mention that the role of syndecan shedding in bacterial internalization is unknown, and the importance of host cell invasion in *P. aeruginosa* pathogenesis is still controversial.

Second, our results show that enhancement of syndecan-1 shedding by *P. aeruginosa* not only dramatically increases the amount of soluble ectodomains, but is also accompanied by a significant decrease in the level of cell surface syndecan-1. This property may be pathologically significant since in a previous study, we have found that expression of syndecan-1 is essential in maintaining the normal phenotype of simple epithelia (69). Antisense induced depletion of cell surface syndecan-1 altered cell morphology and organization, expression of other adhesion molecules like E-cadherin and $\beta 1$ integrins, and anchorage-dependent growth characteristics in NMuMG cells. Because highly polarized epithelia is thought of as an effective barrier against microbial colonization (45,46), the concomitant decrease of cell surface syndecan-1 levels observed during LasA-enhanced shedding can potentially enhance *P. aeruginosa* colonization by altering the morphology of target epithelia, disrupting

the polarity of the epithelial barrier and exposing intercellular, basolateral and subepithelial adhesive components.

Alternatively, syndecan-1 shedding enhanced by LasA may contribute to *P. aeruginosa* pathogenesis by interfering with host defense mechanisms. For example, HS chains of shed syndecan-1 ectodomains can bind and modulate the activity of a plethora of host defense effectors such as chemokines, cytokines and proteases (36). Furthermore, we have found in a separate study that shed syndecan-1 ectodomains can inhibit the antibacterial activity of Pro/Arg-rich antimicrobial peptides by binding to the peptides and preventing them from interacting with target bacterial cells (unpublished results). These potentially pro-pathogenic activities indicate that shed syndecan-1 ectodomains may act as host-derived effectors in the virulence mechanism mediated by LasA. To further decipher the role of enhanced shedding in *P. aeruginosa* pathogenesis, we are currently evaluating the role of syndecan-1 shedding in murine models of bacterial infection using specific agonists and antagonists of syndecan shedding, and also using mice lacking syndecan-1 or overexpressing a constitutively shed form of syndecan-1.

Table 1

Amino Terminal Sequencing of the 20 kDa Putative
Syndecan-1 Shedding Enhancer Isolated from *P. aeruginosa*

The 20 kDa shedding enhancer, partially purified by ammonium sulfate precipitation and gel chromatography, was subjected to 12% SDS-PAGE and electrophoretically transferred to Problott PVDF membrane for 1 h at 200 mA using CAPS transfer buffer (10 mM CAPS, pH 11, 10% MeOH in de-ionized H₂O). The 20 kDa band was visualized by Coomassie Brilliant blue R-250 staining, destained, washed extensively with de-ionized water, excised from the membrane and sequenced directly using an Applied Biosystems 477A protein sequencer at the Department of Physiology Core Facility at Tufts University Medical School.

	5	10
20 kDa protein	A P P S N L M Q L P	
Mature LasA	A P P S N L M Q L P	

Table 2

Effects of Inhibitors on Syndecan-1 Shedding
Enhanced by Purified LasA and *P. aeruginosa* supernatant

- 5 Confluent cultures of NMuMG cells in 96 well plates were incubated with purified LasA (5 µg/ml) or BL2 supernatant (20%, v/v) with or without the hydroxamate and signaling inhibitors for 6h at 37°C. Alternatively, purified LasA was pre-incubated with the inhibitors for 3 h at 37°C, centrifuged against a 10 kDa MWCO membrane to remove the inhibitors and then incubated with NmuMG cells for 6h at 37°C (ND=not
10 determined).

2. <u>Inhi</u> <u>bitors</u>	II. SYNDECAN-1 ECTODOMAIN SHED (mean % of controls \pm SD)
Co-incubated	Purified LasA <i>P. aeruginosa</i> supernatant
None	100.0 \pm 9.5 100.0 \pm 8.7
BB1101	
2 µM	28.5 \pm 2.7 22.1 \pm 10.3
0.2 µM	40.2 \pm 8.7 33.6 \pm 23.7
Bisindolylmaleimide	
1 µM	81.8 \pm 4.4 88.7 \pm 1.8
0.2 µM	85.0 \pm 18.8 111.6 \pm 13.4
Genistein	
10 µg/ml	54.4 \pm 22.7 55.6 \pm 14.1
0.2 µg/ml	74.0 \pm 4.4 75.9 \pm 8.9
Tyrphostin	
10 µg/ml	36.5 \pm 5.3 31.6 \pm 11.61
0.2 µg/ml	78.3 \pm 12.6 80.5 \pm 6.5
Pre-treated	
None	100.0 \pm 9.5 ND
BB1101 (2 µM)	89.6 \pm 11.6 ND
Bisindolylmaleimide (1µM)	81.5 \pm 15.5 ND
Genistein (10 µg/ml)	98.2 \pm 1.3 ND
Tyrphostin (10 µg/ml)	105.5 \pm 9.3 ND

Example 2

Procedure for *In Vivo* Inhibition of Syndecan-1 Shedding Examining
the Effects of Heparin (mimics shed syndecan-1 ectodomains) and
BB1101 (inhibits shedding).

1) 7d old mouse pups were pre-inoculated intranasally with 20 μ M
BB1101. One hour later, mice were inoculated intranasally with approximately 2×10^9
cfus of *P. aeruginosa* strain PAO1 in 7 μ l TSB.

2) For animals with heparin, mice were inoculated intranasally with 2×10^9
cfus of bacteria in 7 μ l of TSB containing 5 μ g/ml heparin.

3) Both set of animals were processed the following day for lung
(pneumonia) and spleen (bacteremia) colony counts.

Condition	Lung Colonization (mean cfus/mg tissue+ geometric mean)	Bacteremia (spleen)	Mortality
Bacteria only	$1.1 \times 10^6 \pm 3.3 \times 10^5$	$1.4 \times 10^5 \pm 3.0 \times 10^4$	4/10
+ 20 μ M BB1101	$4.3 \times 10^4 \pm 6.3 \times 10^3$	695.0 ± 437.0	0/5
+ 5 μ g/ml heparin	$3.6 \times 10^7 \pm 3.7 \times 10^6$	$7.3 \times 10^5 \pm 3.2 \times 10^5$	6/7
+ 5 μ g/ml synd-1	$1.4 \times 10^6 \pm 1.0 \times 10^6$	$3.9 \times 10^5 \pm 1.6 \times 10^5$	5/7

These experiments show that *Pseudomonas aeruginosa*-enhanced
shedding of syndecan-1 promotes lung infection by this pathogen. Creating an
environment which mimics excess shedding of syndecan-1 (heparin, purified
syndecan-1 ectodomain) further promotes lung colonization whereas inhibition of
shedding (BB101) prevents lung infection.

Results from Infection Experiments

Bacterium: *Pseudomonas aeruginosa* (strain PAO1)

Mouse: 7-d old Syndecan-1 null ("KO") or wild type ("WT") in C57/BL or Balb/c backgrounds

Intranasal Inoculum: 2×10^9 cfus in 7 μ l TSB

Incubation: 24 hours at room temperature

10	Mouse Strain	Lung Colonization (mean cfus/mg tissue + geometric mean)	Bacteremia (spleen) (mean cfus/mg tissue + geometric mean)	Mortality
	C57/BL-WT (n=6)	$9.9 \times 10^5 \pm 2.61 \times 10^4$	$6.8 \times 10^4 \pm 1.1 \times 10^4$	1/6
	C57/BL-KO (n=4)	19.0 ± 1.4	2.0 ± 0.3	0/4
	Balb/c-WT (n= 8)	$1.6 \times 10^6 \pm 1.0 \times 10^5$	$9.5 \times 10^4 \pm 1.3 \times 10^3$	8/18
15	Balb/c-KO (n=4)	260.0 ± 4.5	167.0 ± 0.9	0/4

These results indicate that mice lacking syndecan-1 are resistant to *Pseudomonas aeruginosa* lung infection relative to their wild type controls.

20

Bacterium: *Pseudomonas aeruginosa* (strain PAO1)

Inoculum: intraperitoneal

Incubation: 24 hours at room temperature

25

30	Mouse Strain	Lung Colonization (mean cfus/mg tissue + geometric mean)	Bacteremia (spleen) (mean cfus/mg tissue + geometric mean)	Mortality
	Balb/c-WT 3.3x10 ⁷ cfus (n=6)	$1.4 \times 10^6 \pm 5.5 \times 10^5$	$6.8 \times 10^4 \pm 1.2 \times 10^4$	3/6
	C57/BL-KO 1.7x10 ⁷ cfus (n=3)	$1.1 \times 10^6 \pm 5.5 \times 10^5$	$6.7 \times 10^4 \pm 1.7 \times 10^4$	2/3

35

These results indicate that resistance is specific to lung infection in that there is no difference in pathogenesis with intraperitoneal inoculation. These

results further indicate that epithelial syndecan-1 can promote infection whereas lack of syndecan-1 can provide resistance.

Example 3

5

Effects of PTK Inhibitors on Syndecan-1 Ectodomain Shedding enhanced by Purified LasA

Condition	PTK Specificity	Syndecan-1 Ectodomain Shed (mean % of control \pm SD)
LasA (5 μ g/ml)		100.0 \pm 18.4
+herbimycin A	Src family PTKs	
5 μ M		40.3 \pm 13.7
1 μ M		54.0 \pm 10.4
+PP2 (calbiochem)	Fyn & LCK	
250 μ M		91.8 \pm 13.2
50 μ M		120.3 \pm 18.7
+AG490 (calbiochem)	JAK2	
1 μ M		120.6 \pm 13.9
200 nM		97.1 \pm 11.5

10 Confluent cultures of NMuMG cells in 96 well plates were incubated with purified LasA (5 μ g/ml) with or without the PTK inhibitors for 6 h at 37°C.

Extent of shedding was quantified by the dot immunoblotting method.

These results show that *Pseudomonas aeruginosa* enhanced shedding requires Src PTK activity.

REFERENCES

1. Hooper, N. M., Karran, E. H., and Turner, A. J. (1997) *Biochem. J.* **321**, 265-279
2. Rose-John, S., and Heinrich, P. C. (1994) *Biochem. J.* **300**, 281-290
3. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massague, J. (1996) *J. Biol. Chem.* **271**, 11376-11382
4. Kahn, J., Ingraham, R. H., Shirley, F., Migaki, G. I., and Kishimoto, T. K. (1994) *J. Cell Biol.* **125**, 461-470
5. Bazil, V., and Strominger, J. L. (1991) *J. Immunol.* **147**, 1567-1574
6. Dempsey, P. J., Meise, K. S., Yoshitake, Y., Nishikawa, K., and Coffey, R. J. (1997) *J. Cell Biol.* **138**, 747-758
7. Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torrance, D. S., Otte-Evans, C., Greenstreet, T., Weerawarna, K., Kronheim, S. R., Petersen, M., Gerhart, M., Kozlosky, C. J., March, C. J., and Black, R. A. (1994) *Nature* **370**, 218-220
8. McGeehan, G. M., Becherer, J. D., Bast, R. C. J., Boyer, C. M., Champion, B., Connolly, K. M., Conway, J. G., Furdon, P., Karp, S., Kidao, S., McElroy, A. B., Nichols, J., Pryzwansky, K. M., Schoenen, F., Sekut, L., Truesdale, A., Verghese, M., Warner, J., and Ways, J. P. (1994) *Nature* **370**, 558-561
9. Engelmann, H., Novick, D., and Wallach, D. (1990) *J. Biol. Chem.* **265**, 1531-1536
10. Brakebusch, C., Varfolomeev, E. E., Batkin, M., and Wallach, D. (1994) *J. Biol. Chem.* **269**, 32488-32496
11. Mullberg, J., Durie, F. H., Otten-Evans, C., Alderson, M. R., Rose-John, S., Cosman, D., Black, R. A., and Mohler, K. M. (1995) *J. Immunol.* **155**, 5198-5205
12. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. (1995) *EMBO J.* **14**, 1129-1135
13. Pandiella, A., and Massague, J. (1991) *J. Biol. Chem.* **266**, 5769-5773
14. Jones, S. A., Novick, D., Horiuchi, S., Yamamoto, N., Szalai, A. J., and Fuller, G. M. (1999) *J. Exp. Med.* **189**, 599-604
15. Manna, S. K., and Aggarwal, B. B. (1998) *J. Biol. Chem.* **273**, 33333-33341

16. Subramanian, S. V., Fitzgerald, M. L., and Bernfield, M. (1997) *J. Biol. Chem.* **272**, 14713-14720
17. Frey, M., Appenheimer, M. M., and Evans, S. S. (1997) *J. Immunol.* **158**, 5424-5434
18. Bennet, T. A., Lynam, E. B., Sklar, L. A., and Rogelj, S. (1996) *J. Immunol.* **156**, 3093-3097
19. Fitzgerald, M. L., Park, P. W., Wang, Z., Chun, J.-S., Murphy, G., and Bernfield, M. (1999) *J. Cell Biol.* **submitted**
20. Isberg, R. R., and Leong, J. M. (1990) *Cell* **60**, 861-871
21. Relman, D., Tuomanen, E., Falkow, S., Golenbock, D. T., Saukkonen, K., and Wright, S. D. (1990) *Cell* **61**, 1375-1382
22. Leininger, E., Roberts, M., Kenimer, J. G., Charles, I. G., Fairweather, N., Novotny, P., and Brennan, M. J. (1991) *Proc. Natl. Acad. Sci.* **88**, 345-349
23. Wickman, T. J., Mathias, P., Cheresch, D. A., and Nemerow, G. R. (1993) *Cell* **73**, 309-319
24. Isberg, R. R., and Tran Van Nhieu, G. (1994) *Trends Microbiol.* **2**, 10-14
25. Finlay, B. B., and Cossart, P. (1997) *Science* **276**, 718-725
26. Suter, S. (1994) *Am. J. Respir. Crit. Care Med.* **150**, S118-S122
27. Travis, J., Potempa, J., and Maeda, H. (1995) *Trends Microbiol.* **3**, 405-407
28. Okamoto, T., Akaike, T., Suga, M., Tanase, S., Horie, H., Miyajima, S., Ando, M., Ichinose, Y., and Maeda, H. (1997) *J. Biol. Chem.* **272**, 6059-6066
29. Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U., Di Padova, F., Schreier, M., and Brade, H. (1994) *FASEB J.* **8**, 217-225
30. Walev, I., Vollmer, P., Palmer, M., Bhakdi, S., and Rose-John, S. (1996) *Proc. Natl. Acad. Sci.* **93**, 7882-7887
31. Vollmer, P., Walev, I., Rose-John, S., and Bhakdi, S. (1996) *Infect. Immun.* **64**, 3646-3651
32. Mattson, E., Van Dijk, H., Verhoef, J., Norrby, R., and Rollof, J. (1996) *Infect. Immun.* **64**, 4351-4355
33. Blum, H., Wolf, M., Enssle, K., Rollinghoff, M., and Gessner, A. (1996) *J. Immunol.* **157**, 1846-1853

34. Hayashi, J., Masaka, T., and Ishikawa, I. (1999) *Infect. Immun.* **67**, 417-420
35. Munk, M. E., Anding, P., Schettini, A. P. M., Cunha, M. G. S., and Kaufman, S. H. E. (1999) *Infect. Immun.* **67**, 423-425
36. Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) *Annu. Rev. Biochem.* **in press**
37. Grassmé, H., Gulbins, E., Brenner, B., Ferlinz, K., Sandhoff, K., Harzer, K., Lang, F., and Meyer, T. F. (1997) *Cell* **91**, 605-615
38. Rostand, K. S., and Esko, J. D. (1997) *Infect. Immun.* **65**, 1-8
39. Kato, M., Wang, H., Kainulainen, V., Fitzgerald, M. L., Ledbetter, S., Ornitz, D. M., and Bernfield, M. (1998) *Nat. Med.* **4**, 691-697
40. Kainulainen, V., Wang, H., Schick, C., and Bernfield, M. (1998) *J. Biol. Chem.* **273**, 11563-11569
41. Kim, C. W., Goldberger, O. A., Gallo, R. L., and Bernfield, M. (1994) *Mol. Biol. Cell* **5**, 797-805
42. Krivan, H. C., Roberts, D. D., and Ginsburg, V. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 6157-6161
43. Jalkanen, M., Nguyen, H., Rapraeger, A., Kurn, N., and Bernfield, M. (1985) *J. Cell Biol.* **101**, 976-984
44. Hansen, M. B., Nielsen, S. E., and Berg, K. (1989) *J. Immunol. Methods* **119**, 203-210
45. Kagnoff, M. F., and Eckmann, L. (1997) *J. Clin. Invest.* **100**, 6-10
46. Wick, M. J., Madara, J. L., Fields, B. N., and Normark, S. J. (1991) *Cell* **67**, 651-659
47. Akiyama, T., and Ogawara, H. (1991) *Methods Enzymol.* **201**, 362-370
48. Gazit, A., Yaish, P., Gilon, C., and Levitzki, A. (1989) *J. Med. Chem.* **32**, 2344-2352
49. Wojtowicz-Praga, S. M., Dickson, R. B., and Hawkins, M. J. (1997) *Invest. New Drugs* **15**, 61-75
50. Peters, J. E., and Galloway, D. R. (1990) *J. Bacteriol.* **172**, 2236-2240
51. Kessler, E., Safrin, M., Gustin, J. K., and Ohman, D. E. (1998) *J. Biol. Chem.* **273**, 30225-30231
52. Kessler, E., Safrin, M., Abrams, W. R., Rosenbloom, J., and Ohman, D. E.

- (1997) *J. Biol. Chem.* **272**, 9884-9889
53. Gustin, J. K., Kessler, E., and Ohman, D. E. (1996) *J. Bacteriol.* **178**, 6608-6617
54. Galloway, D. R. (1991) *Mol. Microbiol.* **5**(10), 2315-2321
55. Reiland, J., Ott, V. L., Lebakken, C. S., Yeaman, C., McCarthy, J., and Rapraeger, A. C. (1996) *Biochem. J.* **319**, 39-47
56. Kinnunen, T., Kaksonen, M., Saarinen, J., Kalkkinen, N., Peng, H. B., and Rauvala, H. (1998) *J. Biol. Chem.* **273**, 10702-10708
57. Ott, V. L., and Rapraeger, A. C. (1998) *J. Biol. Chem.* **273**, 35291-35298
58. Preston, M. J., Seed, P. C., Toder, D. S., Iglewski, B. H., Ohman, D. E., Gustin, J. K., Goldberg, J. B., and Pier, G. B. (1997) *Infect. Immun.* **65**, 3086-3090
59. Woods, D. E., Cryz, S. J., Friedman, R. L., and Iglewski, B. H. (1982) *Infect. Immun.* **36**, 1223-1228
60. Blackwood, L. L., Stone, R. M., Iglewski, B. H., and Pennington, J. E. (1983) *Infect. Immun.* **39**, 198-201
61. Bliska, J. B., Galán, J. E., and Falkow, S. (1993) *Cell* **73**, 903-920
62. Evans, D. J., Frank, D. W., Finck-Barbançon, V., Wu, C., and Fleiszig, S. M. J. (1998) *Infect. Immun.* **66**, 1453-1459
63. Finlay, B. B., and Falkow, S. (1989) *Microbiol. Rev.* **53**, 210-230
64. Tang, P., Sutherland, C. L., Gold, M. R., and Finlay, B. B. (1998) *Infect. Immun.* **66**, 1106-1112
65. Fleiszig, S. M. J., Zaidi, T. S., and Pier, G. B. (1995) *Infect. Immun.* **63**, 4072-4077
66. Fleiszig, S. M., Evans, D. J., Do, N., Vallas, V., Shin, S., and Mostov, K. E. (1997) *Infect. Immun.* **65**, 2861-2867
67. Hauser, A. R., Fleiszig, S., Kang, P. J., Mostov, K., and Engel, J. N. (1998) *Infect. Immun.* **66**, 1413-1420
68. Pier, G. B., Grout, G., Zaidi, T. S., Olsen, J. C., Johnson, L. G., Yankaskas, J. R., and Goldberg, J. B. (1996) *Science* **271**, 64-67
69. Kato, M., Saunders, S., Nguyen, H., and Bernfield, M. (1995) *Mol. Biol. Cell* **6**, 559-576

70. Shanson D.C. (1986) *Br. J. Hosp. Med.* 35(5):312, 314, 318-320.
71. Wiblin R.T. (1997) Nosocomial pneumonia. In: Wenzel R.P., editor. Prevention and control of nosocomial infections. 3RD ed. Baltimore: Williams and Wilkins; p. 807-819.
72. Van Delden C., et al. (1998) *Emerg. Infect. Dis.* 4(4):551-560.
73. Fergie J.E., et al. (1994) *Clin. Infect. Dis.* (18):390-394.
74. Bergen G.A., et al. (1996) *Infect. Dis. Clin. North Am.* (10):297-326.
75. Dunn M., et al. (1995) *Clinics in Chest Med.* (16):95-109.
76. Pollack M. (1995) *Pseudomonas aeruginosa*. In: Mandell G.L., Benett J.E., Dolin R, editors. Principles and practice of infectious diseases. 4TH ed. New York: Churchill Livingstone; p. 1980-2003.
77. Kluytmans J. (1997) Surgical infections including burns. In Wenzel R.P., editor. Prevention and control of nosocomial infections. 3RD ed. Baltimore: Williams and Wilkins; p. 841-865.
78. Gordon S.M., et al. (1998) *Ann. Thorac. Surg.* (65):95-100.
79. Mendelson M.H., et al. (1994) *Clin. Infect. Dis.* (18):886-895.
80. Govan J.R., et al. (1996) *Microbiol. Rev.* 60:539-574.
81. Pier G.B. (1998) *ASM News* 64(6):339-347.
82. Murray B. E. (1989) *Infect. Dis. Clin. North Am.* 3(3):423-4339.
83. Thornsberry C. (1988) *J. Antimicrob. Chemother.* Apr;21 Suppl. C:9-17.
84. Swartz M.N. (1994) *Proc. Natl. Acad. Sci. U.S.A.* 91(7):2420-2427.
85. Murray B.E. (1991) *J. Infect. Dis.* 163(6):1184-1194.
86. Lacey R.W. , et al. (1986) *J. Antimicrob. Chemother.* Oct;18 Suppl. C:207-214.
87. Turnidge J., et al. (1989) *Med. J. Aust.* 16;150(2):65, 69-72.
88. McManus J. (1999) *B.M.J.* 318(7184):626.
89. Hiramatsu, K., et al (1998) *Am. J. Med.* 104(5A):7S-10S.

90. Hiramatsu K., et al. (1997) *Lancet* 350(9092):1670-3.
91. Sieradzki K., et al. (1999) *N. Engl. J. Med.* 340(7):517-523.
92. Russell A.D. (1997) *J. Appl. Microbiol.* 83(2):155-165.
93. Van Bambeke F., et al. (1999) *Antimicrob. Agents Chemother.* 43(1):41-47.
94. Passador L., et al. (1995) Quorum sensing and virulence gene regulation in *Pseudomonas aeruginosa*. In: Roth J.A., editor. *Virulence mechanisms of bacterial pathogens*. 2ND ed. Washington: American Society for Microbiology. p.65-78.
95. Richard P., et al. (1994) *J. Infect. Dis.* (170):377-383.
96. Brewer S.C., et al. (1996) *Chest* (109):1019-1029.

All documents mentioned herein are incorporated herein by reference.

The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention.

What is claimed is:

1. A method for treating a bacterial infection comprising:
 - a) determining whether the bacterium causing the infection is capable of enhancing host cell syndecan-1 shedding; and
 - b) administering an effective amount of a compound that inhibits syndecan-1 shedding to a subject suffering from said infection, wherein the compound is selected from (a) inhibitors of a bacterial factor responsible for syndecan-1 cleavage, (b) compounds that bind the syndecan and disrupt cleavage, (c) syndecan-1 decoys, and (d) inhibitors of the host cell shedding mechanism, except when the bacterium is *Pseudomonas aeruginosa*, the compound is not genistein or tyrphostin A47.
2. The method of claim 1, wherein the compound is a hydroxamate derivative or a protein tyrosine kinase inhibitor.
3. The method of claim 2, wherein the compound is a hydroxamate derivative.
4. The method of claim 2, wherein the compound is a protein tyrosine kinase inhibitor.
5. The method of claim 4, wherein the protein tyrosine kinase inhibitor is genistein or tyrphostin A25.
6. The method of claim 1, wherein the compound binds the syndecan and disrupts cleavage.
7. The method of claim 6, wherein the compound that binds the syndecan and disrupts cleavage is an antibody.
8. The method of claim 1, wherein the bacterium is *Pseudomonas aeruginosa*.

9. The method of claim 1, wherein the bacterium is *Staphylococcus aureus*.
10. The method of claim 1, wherein the infection is of the respiratory system, the urinary tract, the skin, the eye (cornea), or bloodstream.
11. A method for treating a *Pseudomonas* or *Staphylococcus* lung infection comprising administering an effective amount of a compound that inhibits syndecan-1 shedding to a subject suffering from said infection, wherein the compound is a hydroxamate derivative, a protein tyrosine kinase inhibitor, or an antibody that binds the syndecan and disrupts cleavage, except the compound is not a protein tyrosine kinase inhibitor when the *Pseudomonas* is *Pseudomonas aeruginosa*.
12. A method of identifying a compound useful in the treatment of a bacterial infection comprising contacting a syndecan-1 containing cell with a candidate pharmacological agent and measuring syndecan-1 cleavage.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17560 A1

(51) International Patent Classification⁷: **A61K 39/395**,
39/02, 39/085, 39/108, C12Q 1/00, 1/18, C07K 1/00,
16/00

(US). PARK, Pyong, Woo [KR/US]; 1277 Commonwealth
Avenue, Allston, MA 02134 (US).

(21) International Application Number: PCT/US00/24839

(74) Agents: RESNICK, David, S. et al.; Nixon Peabody LLP,
101 Federal Street, Boston, MA 02110 (US).

(22) International Filing Date:

11 September 2000 (11.09.2000)

(81) Designated States (*national*): AU, CA, JP, US.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(26) Publication Language: English

(30) Priority Data:

60/153,310 10 September 1999 (10.09.1999) US

Published:

— With international search report.

— Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

(71) Applicant (*for all designated States except US*): CHIL-
DREN'S MEDICAL CENTER CORPORATION
[US/US]; 300 Longwood Avenue, Boston, MA 02115
(US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BERNFIELD, Mer-
ton [US/US]; 25 Brimmer Street, Boston, MA 02108-1040

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

(57) Abstract: The present invention provides methods and compositions for treating bacterial infections, especially infections by opportunistic pathogens in a subject by administering a compound that inhibits syndecan-1 shedding. The invention is based on the discovery that two diverse opportunistic pathogens, *S. aureus* and *P. aeruginosa*, enhance syndecan-1 shedding and that this shedding is critical for *Pseudomonas* pathogenesis via the respiratory tract. The discovery is also based on the surprising finding that inhibition of syndecan-1 shedding prevents *Pseudomonas* pneumonia in a mammalian model. The *P. aeruginosa* shedding enhancer has been purified and identified as the mature 20 kDa LasA protein, a known virulence factor of *P. aeruginosa*.

WO 01/17560 A1

1/9






FIG. 1

2/9

**FIG. 2A**

3/9

**FIG. 2B**

4/9





FIG. 3

5/9

**FIG. 4**

10/070647




FIG. 5

7/9




FIG 6

8/9




FIG. 7

9/9




FIG. 8

NIXON PEABODY LLP
101 Federal Street
Boston, Massachusetts 02110

Attorney's Docket No. 701039-048929

Page 1 of 4

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

which is described and claimed in:

- ☐ the specification attached hereto.
- ☐ the specification in U.S. Application Serial Number _____, filed on _____; and
- ☒ the specification in PCT International Application Number US00/24839 filed on 11 September 2000;

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:			
Application No.	<u>Filing Date</u>	<u>Country</u>	<u>Priority Claimed under 35 U.S.C. §119?</u>
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

NIXON PEABODY LLP
101 Federal Street
Boston, Massachusetts 02110

Attorney's Docket No. 701039-048929

Page 2 of 4

Prior U.S. Applications or PCT International Applications Designating the U.S.-Benefit under 35 U.S.C. § 120					
U.S. Applications			Status (Check One)		
Application Serial No.	U.S. Filing	Patented	Pending	Abandoned	
PCT Applications Designating the U.S.					
Application No.	Filing Date	U.S. Serial No. Assigned			
PCT/US00/24839	11 September 2000	10/070,647		X	

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. § 119(e))**

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

<u>Applicant</u>	<u>Provisional Application Number</u>	<u>Filing Date</u>
Merton Bernfield, et al.	60/153,310	10 September 1999

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I. Eisenstein (Reg. No. 30,628)	David S. Resnick (Reg. No. 34,235)	Michael L. Goldman (Reg. No. 30,727)
Nicole L.M. Valtz (Reg. No. 47,150)	Lana A. Shvartsman (Reg. No. 48,502)	Georgia Evans (Reg. No. 44,957)
Lisa A. Dolak (Reg. No. 35,491)	William T. French (Reg. No. 16,297)	Gunnar G. Leinberg (Reg. No. 35,584)
Edwin V. Merkel (Reg. No. 40,087)	Joseph Noto (Reg. No. 32,163)	

SEND CORRESPONDENCE TO: <u>David S. Resnick</u> <u>NIXON PEABODY LLP</u> <u>101 Federal Street</u> <u>Boston, Massachusetts 02110</u>	DIRECT TELEPHONE CALLS TO: <u>David S. Resnick</u> <u>(617) 345-6057</u>
--	---

NIXON PEABODY LLP
101 Federal Street
Boston, Massachusetts 02110

Attorney's Docket No. 701039-048929

Page 3 of 4

201	FULL NAME OF INVENTOR	LAST NAME *BERNFELD	FIRST NAME MERTON	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY Boston	STATE OR FOREIGN COUNTRY MA	COUNTRY OF CITIZENSHIP US
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 79 Boylston St. Apt. 27C	CITY Boston	STATE OR COUNTRY AND ZIP CODE MA 02199
*Deceased – completed on added page				

202	FULL NAME OF INVENTOR	LAST NAME PARK	FIRST NAME PYONG	MIDDLE NAME WOO
	RESIDENCE & CITIZENSHIP	CITY Allston	STATE OR FOREIGN COUNTRY MA	COUNTRY OF CITIZENSHIP KR
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 1277 Commonwealth Avenue	CITY Boston	STATE OR COUNTRY AND ZIP CODE MA 02134

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

110	Signature of Inventor 201 (*Merton Bernfeld / *Deceased – completed on added page) (Audrey Bernfeld, Executrix)	Date:
	<i>Audrey Bernfeld</i>	6/7/02
	Signature of Inventor 202 (Pyong Woo Park)	Date:
	<i>Pyong Woo Park</i>	6/12/02

ADDED PAGE TO COMBINED DECLARATION AND POWER OF
ATTORNEY FOR SIGNATURE BY ADMINISTRATOR(TRIX), EXECUTOR(TRIX)
OR LEGAL REPRESENTATIVE ON BEHALF OF DECEASED OR
INCAPACITATED INVENTOR (37 C.F.R. SECTIONS 1.42 AND 1.43)

11.00
I, Audrey Bernfield

(type or print name(s) of administrator(trix), executor(trix), legal representative or all heirs)

hereby declare that I am a citizen of US

residing at 790 Baylston Street, Boston, MA 02199 (apt 27c)

and that I am executing and signing the declaration to which this is attached as

(check one):

- ☐ the administrator(trix) of
☒ executor(trix) of the last will and testament of
☐ legal representative (or heirs) of

Merton Bernfield

Full name of (first, second etc.) deceased or incapacitated inventor

United States

Country of citizenship of deceased or incapacitated inventor

Boston, MA

Residence of deceased or incapacitated inventor

790 Boylston Street, Apt. 27C, Boston, MA 02199

Post Office Address of deceased or incapacitated inventor


That, upon information and belief, I aver those facts that the inventor is required to state.

Date: 6-07-02

Audrey Bernfield

Signature of Administrator(trix), Executor(trix), Legal Representative
(or all Heirs)

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*

Some hairy figures are too dark.